New findings that RAD52 is essential for cell viability in BRCA1-, PALB2-, BRCA2- and RAD51 paralog-deficient cells but not in normal cells have suggested that RAD52 may represent an attractive therapeutic target for killing breast cancer and ovarian cancer cells [11]. The gene discussed is RAD52; the disease is ovarian carcinoma.